Shardul Amarchand Mangaldas, JSA act on TruNativ $30 million Series B fundraise

TruNativ, a D2C company offering quality nutrition products, has raised $30 million in a Series B fundraise led by Orbimed. The transaction saw Shardul Amarchand Mangaldas & Co advising TruNativ and JSA Advocates & Solicitors advising OrbiMed Asia V Mauritius Limited. The new capital will be used to enhance offline distribution channels, broaden product range, and accelerate expansion in domestic and international markets.

The recent Series B fundraise by TruNativ has garnered attention in the Indian market. With a $30 million investment led by Orbimed, this transaction marks a significant milestone for the company. The involvement of prominent law firms Shardul Amarchand Mangaldas & Co and JSA Advocates & Solicitors underscores the importance of legal expertise in such high-stakes deals.

TruNativ operates as an internet-first, direct-to-consumer (D2C) company offering a range of quality nutrition products. The company delivers functional foods, including protein supplements, through its website and e-commerce channels. This business model has resonated with consumers seeking convenient access to healthy food options.

The legal aspects of this transaction are equally noteworthy. The engagement of Shardul Amarchand Mangaldas & Co and JSA Advocates & Solicitors highlights the importance of counsel in navigating complex deal structures and ensuring compliance with relevant regulatory requirements.

As TruNativ embarks on its next phase of growth, the $30 million Series B fundraise serves as a testament to the company's potential for expansion. The involvement of prominent law firms underscores the significance of legal expertise in driving business success. Practitioners would do well to monitor this development and consider how similar transactions may impact their own clients' interests.